Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.94

-4.2%

2:16 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (7456)	12/10/2002 1:14:10 PM
From: Sam Citron	Read Replies (2) of 52153

The FDA does not publicly comment on drug reviews, but its concerns about Bexxar will be thoroughly aired on Dec. 17. Can you expound on what "thoroughly aired" means in this context? Let's assume you are wrong and ODAC does not approve Bexxar at this meeting. Will we finally find out what they don't like about it? To echo Jacob Snyder's concerns, does the potential reward really outweigh the obvious risks of investing in a sector where outcomes depend so entirely on opaque black box bureaucratic approval processes? You have no present position in CRXA despite your view that ODAC will vote to approve, so I guess the event risk has you in a box also. So what would it take to move you off the fence? BTW, with a short interest ratio of 17.72, isn't that enough upside juice for you?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next